Boehringer Ingelheim signs a license agreement with Evec Inc. for its fully-human antibody programme
Evec is a bio venture company having its head office in Sapporo, Japan, established in 2003, spun off from Hokkaido University. Evec is specialised in development of a wide spectrum of human monoclonal antibodies in multiple therapeutic areas, such as cancer, inflammatory diseases and infectious diseases by an Epstein-Barr Virus Transformation Method. About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development. For further information, please visit http://www.boehringer-ingelheim.com.